| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4003199 | American Journal of Ophthalmology | 2011 | 12 Pages |
Abstract
The angiographic and tomographic effects after intravitreal inhibition of vascular endothelial growth factor (VEGF) using ranibizumab implicate a pathophysiological role of the VEGF pathway in nonproliferative MacTel type 2. As the morphologic response was not associated with a clear functional benefit, and because of the transient nature of the treatment effect, monthly intravitreal ranibizumab is not recommended for the nonproliferative disease stage of MacTel type 2.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Peter Charbel Issa, Robert P. Finger, Kathrin Kruse, Sönke Baumüller, Hendrik P.N. Scholl, Frank G. Holz,